Drug intelligence / Profile preview

AGT2

Development stage: Unknown
Lead developer: AHN-GOOK PHARMACEUTICAL
Modality: Small Molecules

Overview

AGT2 is a small molecule drug developed by AHN-GOOK PHARMACEUTICAL. It is being investigated primarily for the treatment of primary hypercholesterolemia, a condition characterized by high cholesterol levels in the blood. The drug falls under the therapeutic area of endocrinology and metabolic diseases. As of March 2025, its highest global R&D status is "Pending," with clinical development having reached Phase 3 trials in South Korea for primary hypercholesterolemia. Specific details about its mechanism of action, molecular targets, or additional indications have not been disclosed in public sources[1].

Beyond the preview

Go deeper on AGT2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGT2.

Explore the full profile